Komori
JCR Pharmaceuticals (4552) · InitiativeAdvanced

COVID-19 Infection Prevention and Business Continuity Measures

First written in FY2020. 2 of 3 entries say "Advanced", first in FY2021. Latest entry: FY2022.

3entries
3years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020AdvancedFY2021 – FY20222020: 120202021: 120212022: 12022
Same theme, other companies
Maintaining Product Supply and Business Continuity During COVID-19A theme 178 companies write about · 49 as a headwind · 126 as a tailwind

The whole theme swung hardest in 2026: 1 of 12 companies on the "Worse" side.

28 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 178 companies compared. The sentences above are computed from all 178.
Full recordFilings, disclosures and news, newest first
  1. FY2022AdvancedAnnual report

    「Since mid-March 2020, we have implemented measures to prevent infection among group employees, including working from home wherever possible, mask-wearing, thorough handwashing and gargling, temperature checks, antigen testing once every 2 weeks, workplace COVID-19 vaccinations, and regular alerts on infection prevention from the internal COVID-19 response team.」

    In addition to the existing work-from-home, hygiene and antigen-testing measures, the company implemented workplace vaccinations. It explained that all business activities, including research and development and production, were operating normally, with no business disruptions or delays caused by the pandemic.
  2. FY2021AdvancedAnnual report

    「Since mid-March 2020, we have implemented preventive measures for group employees, including working from home wherever possible, mask-wearing, thorough handwashing and gargling, temperature checks, antigen testing once every 2 weeks, and the dissemination of information within the company by an internal special-response team.」

    As COVID-19 prevention measures, the company implemented working from home, basic hygiene measures, antigen testing once every 2 weeks, and information dissemination by an internal special-response team.
  3. FY2020First statedAnnual report

    「In view of the spread of COVID-19, we established an internal COVID-19 response team to gather necessary information and consider and direct measures aimed at preventing infections while continuing to fulfil our mission as a pharmaceutical company.」

    The company established an infectious disease response team and began measures including working from home, mask-wearing, handwashing and gargling, temperature checks, and refraining from nonessential outings and social gatherings. No group employees had been confirmed to be infected as of the filing date.
Moved together

"Development into a research-driven company with a strong global presence" moved the same way as this thread, in the same document, in 2 of its 3 moves.

222222★123456
  1. ★This thread
  2. 1Development into a research-driven company with a strong global presence2×
  3. 2Commercialization, Joint Research and Licensing of J-Brain Cargo®2×
  4. 3Approval and Application Milestones for the Development Pipeline2×
  5. 4Expanding revenue from core products and strengthening the product portfolio2×
  6. 5Expansion of Proprietary Biopharmaceutical Platform Technology2×
  7. 6Development of a Manufacturing and Cell Processing Center for Investigational Drugs2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
JCR Pharmaceuticals's next results are scheduled for 2026-10-29. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
COVID-19 Infection Prevention and Business Continuity Measures | JCR Pharmaceuticals Co.,Ltd. (4552) | Komori